| Dr Mark J Veronneau, DO | |
|
5322 Ky Route 321, Suite 2, Prestonsburg, KY 41653-9114 | |
| (606) 886-2712 | |
| (606) 886-2713 |
| Full Name | Dr Mark J Veronneau |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 5322 Ky Route 321, Prestonsburg, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932208899 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 02996 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pikeville Medical Center | Pikeville, KY | Hospital |
| Highlands Arh Regional Medical Center | Prestonsburg, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mark Veronneau Plastics And Ent, Pllc | 6002913332 | 2 |
| Pikeville Medical Center Inc | 6709790157 | 314 |
News Archive
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.
News outlets covered the fallout from Friday's House of Representatives vote to allow insurers to renew plans that do not comply with the health law.
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
CongressDaily: "After a day of high emotions and partisan bickering, Senate Finance Chairman Max Baucus announced Thursday the panel will not mark up a bipartisan healthcare overhaul bill before August recess.
› Verified 9 days ago
| Entity Name | Three Rivers Medical Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568567345 PECOS PAC ID: 7315845047 Enrollment ID: O20031219000463 |
News Archive
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.
News outlets covered the fallout from Friday's House of Representatives vote to allow insurers to renew plans that do not comply with the health law.
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
CongressDaily: "After a day of high emotions and partisan bickering, Senate Finance Chairman Max Baucus announced Thursday the panel will not mark up a bipartisan healthcare overhaul bill before August recess.
› Verified 9 days ago
| Entity Name | Pikeville Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528195864 PECOS PAC ID: 6709790157 Enrollment ID: O20040304001281 |
News Archive
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.
News outlets covered the fallout from Friday's House of Representatives vote to allow insurers to renew plans that do not comply with the health law.
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
CongressDaily: "After a day of high emotions and partisan bickering, Senate Finance Chairman Max Baucus announced Thursday the panel will not mark up a bipartisan healthcare overhaul bill before August recess.
› Verified 9 days ago
| Entity Name | Mark Veronneau Plastics & Ent, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316005044 PECOS PAC ID: 6002913332 Enrollment ID: O20070522000441 |
News Archive
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.
News outlets covered the fallout from Friday's House of Representatives vote to allow insurers to renew plans that do not comply with the health law.
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
CongressDaily: "After a day of high emotions and partisan bickering, Senate Finance Chairman Max Baucus announced Thursday the panel will not mark up a bipartisan healthcare overhaul bill before August recess.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark J Veronneau, DO Po Box 513, Staffordsville, KY 41256-0513 Ph: (606) 886-2712 | Dr Mark J Veronneau, DO 5322 Ky Route 321, Suite 2, Prestonsburg, KY 41653-9114 Ph: (606) 886-2712 |
News Archive
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients-aged 16 to 39 with acute lymphoblastic leukemia (ALL)-tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens.
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.
News outlets covered the fallout from Friday's House of Representatives vote to allow insurers to renew plans that do not comply with the health law.
Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.
CongressDaily: "After a day of high emotions and partisan bickering, Senate Finance Chairman Max Baucus announced Thursday the panel will not mark up a bipartisan healthcare overhaul bill before August recess.
› Verified 9 days ago
Dr. William Brian Helton, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5322 Ky Route 321, Suite 2, Prestonsburg, KY 41653 Phone: 606-886-2712 Fax: 606-886-2713 |